Cephalosporin Drugs Market - Global Industry Analysis

Cephalosporin Drugs Market Size by Generation, Route of Drug Administration, Application, and Region - Segment-Level Market Assessment, Growth Opportunity Analysis, Competitive Mapping & Forecast to 2032

2.59%

CAGR (2026-2032)

15.8 USD Bn.

Market Size

327

Report Pages

148

Market Tables

Overview

Cephalosporin Drugs Market is expected to reach USD 15.8 Bn. at a CAGR of 2.59% during the forecast period 2032.

Cephalosporin Drugs Market Product Definition

The cephalosporins are a category of β-lactam antibiotics initially derived from the fungus Acremonium, which turned into previously known as Cephalosporium. These prevent the growth of bacteria by using inhibiting cell wall synthesis, which powerful in each sort of microorganism i.e., gram- positive and gram-negative.

Global Cephalosporin Drugs Market Analysis And Forecast

To know about the Research Methodology :- Request Free Sample Report

Global Cephalosporin Drugs Market Definition:

Rising the incidence of infectious diseases, growing cognizance among patients about these drugs, a couple of treatment options and increasing demand for anti-microbial in several signs are considered to be prime factors propelling the growth of the cephalosporin drug market. The report study has analyzed revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers and market disrupters in the report and same is reflected in our analysis.

Global Cephalosporin Drugs Market Dynamics:

The important factors for the growth of the cephalosporin drugs market consist of the growing demand for anti-microbial in various indications, growing occurrence of infectious diseases, and growing use of aggregate treatment options. There are over 50 cephalosporin pills that have been approved in the beyond 5 decades, and almost half of them are for the antibacterial activity. Though, new cephalosporins (classified because the fifth-generation), which can be used for the treatment of severe gram-negative bacterial infections, containing methicillin-resistant Staphylococcus aureus (MRSA), were recently authorised. Manufacturers are concerned in the development of novel drugs to fight against anti-microbial resistance.

The complexity and diversity of resistance mechanisms have described the need for new and stepped forward β-lactam antibiotics. Thus, as a result of the all above-noted factors the cephalosporin drug marketplace is anticipated to see excessive growth above the estimate duration.

Cephalosporin tablets are used to treat with infections in different parts of the body consisting of the ears, lungs, sinuses, throat, nostril, and skin. Physicians also prescribe those tablets to deal with pneumonia, staph infections, bronchitis, strep throat, tonsillitis, and gonorrhea. Cephalosporin drugs can be categorised into 5 classes or generations depending upon antimicrobial activity.

The gram-negative antimicrobial properties extensively upsurge with each more recent technology of cephalosporin. Hence, the use of cephalosporin in diverse disease conditions is probable to enhance the growth of the worldwide cephalosporin drugs market throughout the forecast period. The global cephalosporin capsules market is anticipated to develop notably owing to growing demand for anti-microbial in various symptoms, growing research and development activities, developing awareness amongst patients, rising incidence of infectious diseases, and unique regulatory designation for pipeline molecule.

Global Cephalosporin Drugs Market Segment analysis:

Based at the Generation, the fifth-generation cephalosporins segment is projected to grow at a highest CAGR during the forecast period. The fifth-technology cephalosporins were established in the lab to mainly target resistant strains of bacteria. In unique, ceftobiprole is effective against methicillin-resistant staphylococcus aureus (MRSA). These agents are every so often known as the superior generation, instead of fifth- generation cephalosporins. Cephalosporins exhibit side results similar to penicillin, and drug-hypersensitivity and hypersensitivity. Cephalosporins, generally, related to little hepatotoxicity and rare cases of drug induced liver injury. The fifth-generation cephalosporins contain Ceftolozan, Ceftaroline, and Ceftobiprole. Ceftobiprole has effective antipseudomonal characteristics and seems to be fewer susceptible to the improvement of resistance.

Global Cephalosporin Drugs Market Regional analysis:

The Asia Pacific dominated the global cephalosporin drugs market due to increasing cognizance about cephalosporin drugs amongst patients, growing demand for highly developed health care infrastructure, and a massive populace with infectious diseases. Moreover, the demand for government initiatives is anticipated to support the growth of the market in this region.

North America is considered to be the most attractive market owing to the up surging healthcare expenses, rising occurrence of bacterial infectious diseases, increasing FDA approvals and surging government support for the treatment of various infections. For example, newly the U.S. FDA approved TEFLARO’ a new Drug Application (NDA) developed by Allergen pharmaceuticals, which is used for treatment of acute bacterial skin infections of Staphylococcus aureus. Additionally, the increasing prescription of cephalosporin drug for the treatment of a many diseases is thrusting market growth.

The objective of the report is to present a comprehensive analysis of the Global Cephalosporin Drugs Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market has been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analysed, which will give a clear futuristic view of the industry to the decision-makers.
The report also helps in understanding Global Cephalosporin Drugs Market dynamics, structure by analysing the market segments and projects the Global Cephalosporin Drugs Market size. Clear representation of competitive analysis of key players by Application, price, financial position, Product portfolio, growth strategies, and regional presence in the Global Cephalosporin Drugs Market make the report investor’s guide.

Global Cephalosporin Drugs Market Scope: Inquire before buying

Global Cephalosporin Drugs Market
Report Coverage	Details
Base Year:	2025	Forecast Period:	2026-2032
Historical Data:	2020 to 2025	Market Size in 2025:	15.8 USD Bn.
Forecast Period 2026-2032 CAGR:	2.59%	Market Size in 2032:	18.9 USD Bn.
Segments Covered:	by Generation	Fifth-generation Fourth-generation First-generation Second-generation Third-generation
	by Route of Drug Administration	Injection Oral
	by Application	Respiratory Tract Infection Skin Infection Ear Infection Urinary Tract Infection Sexually Transmitted Infection Others

Global Cephalosporin Drugs Market, by Regions:

North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America)

Key Players / Competitors Profiles Covered in Brief in Global Cephalosporin Drugs Market Report in Strategic Perspective:

1. Aristo Pharmaceuticals Ltd
2. Baxter International
3. F. Hoffmann-La Roche AG
4. GlaxoSmithKline PLC
5. Lupin Pharmaceuticals Inc.
6. Macleods Pharmaceuticals Ltd
7. Mankind Pharma
8. Merck & Co. Inc.
9. Pfizer Inc.
10.Teva Pharmaceutical Industries Ltd
11.Orchid Pharma
12.Taj Pharmaceuticals
13.Covalent Laboratories
14.United Laboratories
15.Aurobindo
16.ABBOTT Laboratories
17.Astellas Pharma Inc.
18.Sanofi
19.Sun Pharmaceutical Industries Limited
20.Allergan Plc.
21.Bayer AG
22.BRISTOL-MYERS SQUIBB COMPANY

Key Recent Developments :

Exact Date	Company	Development	Impact
12 February 2026	Basilea / Venatorx	Announced Phase 3 clinical trial completion for ceftibuten-ledaborbactam etzadroxil, a novel oral cephalosporin combination for complicated urinary tract infections.	Establishes a new outpatient treatment paradigm for multi-drug resistant infections, reducing reliance on hospital-based intravenous therapy.
15 January 2026	F. Hoffmann-La Roche Ltd	Completed a USD 50 billion investment in U.S. manufacturing facilities to scale production of advanced injectable cephalosporin formulations.	Significantly bolsters supply chain resilience and domestic capacity for critical-care antibiotics in the North American market.
18 November 2025	Dechra	Launched Solovecin (cefovecin sodium) in the United States, a long-acting injectable cephalosporin targeting persistent skin infections.	Captures a dominant share of the specialty injectable market by offering extended therapeutic windows with a single dose.
15 August 2025	Merck & Co. Inc	Operationalized a major production expansion for ZERBAXA (cefepime-tazobactam) to address the global surge in ESBL-producing bacterial strains.	Strengthens Merck's competitive positioning in the hospital-acquired infection segment through improved global availability of high-tier antibiotics.
22 May 2025	Innoviva Specialty Therapeutics	Announced the full commercial availability of ZEVTERA (ceftobiprole medocaril) in the U.S. for treating Staphylococcus aureus bloodstream infections.	Provides a first-in-class advanced-generation option for complex bacteremia, filling a critical gap in MRSA treatment protocols.
14 January 2025	UK Health Security Agency	Officially reclassified four cephalosporins, including cefazolin and cefalexin, from the 'Watch' to 'Access' category in national clinical guidelines.	Drives increased prescription volumes by endorsing these drugs as first-line therapies for common infections under stewardship frameworks.

Global Cephalosporin Drugs Market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Cephalosporin Drugs Market Size, by Market Value (USD Bn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Global Cephalosporin Drugs Market Analysis and Forecast 6.1. Global Cephalosporin Drugs Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global Cephalosporin Drugs Market Analysis and Forecast, By Generation 7.1. Introduction and Definition 7.2. Key Findings 7.3. Global Cephalosporin Drugs Market Value Share Analysis, By Generation 7.4. Global Cephalosporin Drugs Market Size (USD Bn) Forecast, By Generation 7.5. Global Cephalosporin Drugs Market Analysis, By Generation 7.6. Global Cephalosporin Drugs Market Attractiveness Analysis, By Generation 8. Global Cephalosporin Drugs Market Analysis and Forecast, By Route of Drug Administration 8.1. Introduction and Definition 8.2. Key Findings 8.3. Global Cephalosporin Drugs Market Value Share Analysis, By Route of Drug Administration 8.4. Global Cephalosporin Drugs Market Size (USD Bn) Forecast, By Route of Drug Administration 8.5. Global Cephalosporin Drugs Market Analysis, By Route of Drug Administration 8.6. Global Cephalosporin Drugs Market Attractiveness Analysis, By Route of Drug Administration 9. Global Cephalosporin Drugs Market Analysis and Forecast, By Application 9.1. Introduction and Definition 9.2. Key Findings 9.3. Global Cephalosporin Drugs Market Value Share Analysis, By Application 9.4. Global Cephalosporin Drugs Market Size (USD Bn) Forecast, By Application 9.5. Global Cephalosporin Drugs Market Analysis, By Application 9.6. Global Cephalosporin Drugs Market Attractiveness Analysis, By Application 10. Global Cephalosporin Drugs Market Analysis, by Region 10.1. Global Cephalosporin Drugs Market Value Share Analysis, by Region 10.2. Global Cephalosporin Drugs Market Size (USD Bn) Forecast, by Region 10.3. Global Cephalosporin Drugs Market Attractiveness Analysis, by Region 11. North America Cephalosporin Drugs Market Analysis 11.1. Key Findings 11.2. North America Cephalosporin Drugs Market Overview 11.3. North America Cephalosporin Drugs Market Value Share Analysis, By Generation 11.4. North America Cephalosporin Drugs Market Forecast, By Generation 11.4.1. First-generation 11.4.2. Second-generation 11.4.3. Third-generation 11.4.4. Fourth-generation 11.4.5. Fifth-generation 11.5. North America Cephalosporin Drugs Market Value Share Analysis, By Route of Drug Administration 11.6. North America Cephalosporin Drugs Market Forecast, By Route of Drug Administration 11.6.1. Injection 11.6.2. Oral 11.7. North America Cephalosporin Drugs Market Value Share Analysis, By Application 11.8. North America Cephalosporin Drugs Market Forecast, By Application 11.8.1. Respiratory Tract Infection 11.8.2. Skin Infection 11.8.3. Ear Infection 11.8.4. Urinary Tract Infection 11.8.5. Sexually Transmitted Infection 11.8.6. Others 11.9. North America Cephalosporin Drugs Market Value Share Analysis, by Country 11.10. North America Cephalosporin Drugs Market Forecast, by Country 11.10.1. U.S. 11.10.2. Canada 11.11. North America Cephalosporin Drugs Market Analysis, by Country 11.12. U.S. Cephalosporin Drugs Market Forecast, By Generation 11.12.1. First-generation 11.12.2. Second-generation 11.12.3. Third-generation 11.12.4. Fourth-generation 11.12.5. Fifth-generation 11.13. U.S. Cephalosporin Drugs Market Forecast, By Route of Drug Administration 11.13.1. Injection 11.13.2. Oral 11.14. U.S. Cephalosporin Drugs Market Forecast, By Application 11.14.1. Respiratory Tract Infection 11.14.2. Skin Infection 11.14.3. Ear Infection 11.14.4. Urinary Tract Infection 11.14.5. Sexually Transmitted Infection 11.14.6. Others 11.15. Canada Cephalosporin Drugs Market Forecast, By Generation 11.15.1. First-generation 11.15.2. Second-generation 11.15.3. Third-generation 11.15.4. Fourth-generation 11.15.5. Fifth-generation 11.16. Canada Cephalosporin Drugs Market Forecast, By Route of Drug Administration 11.16.1. Injection 11.16.2. Oral 11.17. Canada Cephalosporin Drugs Market Forecast, By Application 11.17.1. Respiratory Tract Infection 11.17.2. Skin Infection 11.17.3. Ear Infection 11.17.4. Urinary Tract Infection 11.17.5. Sexually Transmitted Infection 11.17.6. Others 11.18. North America Cephalosporin Drugs Market Attractiveness Analysis 11.18.1. By Generation 11.18.2. By Route of Drug Administration 11.18.3. By Application 11.19. PEST Analysis 11.20. Key Trends 11.21. Key Developments 12. Europe Cephalosporin Drugs Market Analysis 12.1. Key Findings 12.2. Europe Cephalosporin Drugs Market Overview 12.3. Europe Cephalosporin Drugs Market Value Share Analysis, By Generation 12.4. Europe Cephalosporin Drugs Market Forecast, By Generation 12.4.1. First-generation 12.4.2. Second-generation 12.4.3. Third-generation 12.4.4. Fourth-generation 12.4.5. Fifth-generation 12.5. Europe Cephalosporin Drugs Market Value Share Analysis, By Route of Drug Administration 12.6. Europe Cephalosporin Drugs Market Forecast, By Route of Drug Administration 12.6.1. Injection 12.6.2. Oral 12.7. Europe Cephalosporin Drugs Market Value Share Analysis, By Application 12.8. Europe Cephalosporin Drugs Market Forecast, By Application 12.8.1. Respiratory Tract Infection 12.8.2. Skin Infection 12.8.3. Ear Infection 12.8.4. Urinary Tract Infection 12.8.5. Sexually Transmitted Infection 12.8.6. Others 12.9. Europe Cephalosporin Drugs Market Value Share Analysis, by Country 12.10. Europe Cephalosporin Drugs Market Forecast, by Country 12.10.1. Germany 12.10.2. U.K. 12.10.3. France 12.10.4. Italy 12.10.5. Spain 12.10.6. Rest of Europe 12.11. Europe Cephalosporin Drugs Market Analysis, by Country 12.12. Germany Cephalosporin Drugs Market Forecast, By Generation 12.12.1. First-generation 12.12.2. Second-generation 12.12.3. Third-generation 12.12.4. Fourth-generation 12.12.5. Fifth-generation 12.13. Germany Cephalosporin Drugs Market Forecast, By Route of Drug Administration 12.13.1. Injection 12.13.2. Oral 12.14. Germany Cephalosporin Drugs Market Forecast, By Application 12.14.1. Respiratory Tract Infection 12.14.2. Skin Infection 12.14.3. Ear Infection 12.14.4. Urinary Tract Infection 12.14.5. Sexually Transmitted Infection 12.14.6. Others 12.15. U.K. Cephalosporin Drugs Market Forecast, By Generation 12.15.1. First-generation 12.15.2. Second-generation 12.15.3. Third-generation 12.15.4. Fourth-generation 12.15.5. Fifth-generation 12.16. U.K. Cephalosporin Drugs Market Forecast, By Route of Drug Administration 12.16.1. Injection 12.16.2. Oral 12.17. U.K. Cephalosporin Drugs Market Forecast, By Application 12.17.1. Respiratory Tract Infection 12.17.2. Skin Infection 12.17.3. Ear Infection 12.17.4. Urinary Tract Infection 12.17.5. Sexually Transmitted Infection 12.17.6. Others 12.18. France Cephalosporin Drugs Market Forecast, By Generation 12.18.1. First-generation 12.18.2. Second-generation 12.18.3. Third-generation 12.18.4. Fourth-generation 12.18.5. Fifth-generation 12.19. France Cephalosporin Drugs Market Forecast, By Route of Drug Administration 12.19.1. Injection 12.19.2. Oral 12.20. France Cephalosporin Drugs Market Forecast, By Application 12.20.1. Respiratory Tract Infection 12.20.2. Skin Infection 12.20.3. Ear Infection 12.20.4. Urinary Tract Infection 12.20.5. Sexually Transmitted Infection 12.20.6. Others 12.21. Italy Cephalosporin Drugs Market Forecast, By Generation 12.21.1. First-generation 12.21.2. Second-generation 12.21.3. Third-generation 12.21.4. Fourth-generation 12.21.5. Fifth-generation 12.22. Italy Cephalosporin Drugs Market Forecast, By Route of Drug Administration 12.22.1. Injection 12.22.2. Oral 12.23. Italy Cephalosporin Drugs Market Forecast, By Application 12.23.1. Respiratory Tract Infection 12.23.2. Skin Infection 12.23.3. Ear Infection 12.23.4. Urinary Tract Infection 12.23.5. Sexually Transmitted Infection 12.23.6. Others 12.24. Spain Cephalosporin Drugs Market Forecast, By Generation 12.24.1. First-generation 12.24.2. Second-generation 12.24.3. Third-generation 12.24.4. Fourth-generation 12.24.5. Fifth-generation 12.25. Spain Cephalosporin Drugs Market Forecast, By Route of Drug Administration 12.25.1. Injection 12.25.2. Oral 12.26. Spain Cephalosporin Drugs Market Forecast, By Application 12.26.1. Respiratory Tract Infection 12.26.2. Skin Infection 12.26.3. Ear Infection 12.26.4. Urinary Tract Infection 12.26.5. Sexually Transmitted Infection 12.26.6. Others 12.27. Rest of Europe Cephalosporin Drugs Market Forecast, By Generation 12.27.1. First-generation 12.27.2. Second-generation 12.27.3. Third-generation 12.27.4. Fourth-generation 12.27.5. Fifth-generation 12.28. Rest of Europe Cephalosporin Drugs Market Forecast, By Route of Drug Administration 12.28.1. Injection 12.28.2. Oral 12.29. Rest Of Europe Cephalosporin Drugs Market Forecast, By Application 12.29.1. Respiratory Tract Infection 12.29.2. Skin Infection 12.29.3. Ear Infection 12.29.4. Urinary Tract Infection 12.29.5. Sexually Transmitted Infection 12.29.6. Others 12.30. Europe Cephalosporin Drugs Market Attractiveness Analysis 12.30.1. By Generation 12.30.2. By Route of Drug Administration 12.30.3. By Application 12.31. PEST Analysis 12.32. Key Trends 12.33. Key Developments 13. Asia Pacific Cephalosporin Drugs Market Analysis 13.1. Key Findings 13.2. Asia Pacific Cephalosporin Drugs Market Overview 13.3. Asia Pacific Cephalosporin Drugs Market Value Share Analysis, By Generation 13.4. Asia Pacific Cephalosporin Drugs Market Forecast, By Generation 13.4.1. First-generation 13.4.2. Second-generation 13.4.3. Third-generation 13.4.4. Fourth-generation 13.4.5. Fifth-generation 13.5. Asia Pacific Cephalosporin Drugs Market Value Share Analysis, By Route of Drug Administration 13.6. Asia Pacific Cephalosporin Drugs Market Forecast, By Route of Drug Administration 13.6.1. Injection 13.6.2. Oral 13.7. Asia Pacific Cephalosporin Drugs Market Value Share Analysis, By Application 13.8. Asia Pacific Cephalosporin Drugs Market Forecast, By Application 13.8.1. Respiratory Tract Infection 13.8.2. Skin Infection 13.8.3. Ear Infection 13.8.4. Urinary Tract Infection 13.8.5. Sexually Transmitted Infection 13.8.6. Others 13.9. Asia Pacific Cephalosporin Drugs Market Value Share Analysis, by Country 13.10. Asia Pacific Cephalosporin Drugs Market Forecast, by Country 13.10.1. China 13.10.2. India 13.10.3. Japan 13.10.4. ASEAN 13.10.5. Rest of Asia Pacific 13.11. Asia Pacific Cephalosporin Drugs Market Analysis, by Country 13.12. China Cephalosporin Drugs Market Forecast, By Generation 13.12.1. First-generation 13.12.2. Second-generation 13.12.3. Third-generation 13.12.4. Fourth-generation 13.12.5. Fifth-generation 13.13. China Cephalosporin Drugs Market Forecast, By Route of Drug Administration 13.13.1. Injection 13.13.2. Oral 13.14. China Cephalosporin Drugs Market Forecast, By Application 13.14.1. Respiratory Tract Infection 13.14.2. Skin Infection 13.14.3. Ear Infection 13.14.4. Urinary Tract Infection 13.14.5. Sexually Transmitted Infection 13.14.6. Others 13.15. India Cephalosporin Drugs Market Forecast, By Generation 13.15.1. First-generation 13.15.2. Second-generation 13.15.3. Third-generation 13.15.4. Fourth-generation 13.15.5. Fifth-generation 13.16. India Cephalosporin Drugs Market Forecast, By Route of Drug Administration 13.16.1. Injection 13.16.2. Oral 13.17. India Cephalosporin Drugs Market Forecast, By Application 13.17.1. Respiratory Tract Infection 13.17.2. Skin Infection 13.17.3. Ear Infection 13.17.4. Urinary Tract Infection 13.17.5. Sexually Transmitted Infection 13.17.6. Others 13.18. Japan Cephalosporin Drugs Market Forecast, By Generation 13.18.1. First-generation 13.18.2. Second-generation 13.18.3. Third-generation 13.18.4. Fourth-generation 13.18.5. Fifth-generation 13.19. Japan Cephalosporin Drugs Market Forecast, By Route of Drug Administration 13.19.1. Injection 13.19.2. Oral 13.20. Japan Cephalosporin Drugs Market Forecast, By Application 13.20.1. Respiratory Tract Infection 13.20.2. Skin Infection 13.20.3. Ear Infection 13.20.4. Urinary Tract Infection 13.20.5. Sexually Transmitted Infection 13.20.6. Others 13.21. ASEAN Cephalosporin Drugs Market Forecast, By Generation 13.21.1. First-generation 13.21.2. Second-generation 13.21.3. Third-generation 13.21.4. Fourth-generation 13.21.5. Fifth-generation 13.22. ASEAN Cephalosporin Drugs Market Forecast, By Route of Drug Administration 13.22.1. Injection 13.22.2. Oral 13.23. ASEAN Cephalosporin Drugs Market Forecast, By Application 13.23.1. Respiratory Tract Infection 13.23.2. Skin Infection 13.23.3. Ear Infection 13.23.4. Urinary Tract Infection 13.23.5. Sexually Transmitted Infection 13.23.6. Others 13.24. Rest of Asia Pacific Cephalosporin Drugs Market Forecast, By Generation 13.24.1. First-generation 13.24.2. Second-generation 13.24.3. Third-generation 13.24.4. Fourth-generation 13.24.5. Fifth-generation 13.25. Rest of Asia Pacific Cephalosporin Drugs Market Forecast, By Route of Drug Administration 13.25.1. Injection 13.25.2. Oral 13.26. Rest of Asia Pacific Cephalosporin Drugs Market Forecast, By Application 13.26.1. Respiratory Tract Infection 13.26.2. Skin Infection 13.26.3. Ear Infection 13.26.4. Urinary Tract Infection 13.26.5. Sexually Transmitted Infection 13.26.6. Others 13.27. Asia Pacific Cephalosporin Drugs Market Attractiveness Analysis 13.27.1. By Generation 13.27.2. By Route of Drug Administration 13.27.3. By Application 13.28. PEST Analysis 13.29. Key Trends 13.30. Key Developments 14. Middle East & Africa Cephalosporin Drugs Market Analysis 14.1. Key Findings 14.2. Middle East & Africa Cephalosporin Drugs Market Overview 14.3. Middle East & Africa Cephalosporin Drugs Market Value Share Analysis, By Generation 14.4. Middle East & Africa Cephalosporin Drugs Market Forecast, By Generation 14.4.1. First-generation 14.4.2. Second-generation 14.4.3. Third-generation 14.4.4. Fourth-generation 14.4.5. Fifth-generation 14.5. Middle East & Africa Cephalosporin Drugs Market Value Share Analysis, By Route of Drug Administration 14.6. Middle East & Africa Cephalosporin Drugs Market Forecast, By Route of Drug Administration 14.6.1. Injection 14.6.2. Oral 14.7. Middle East & Africa Cephalosporin Drugs Market Value Share Analysis, By Application 14.8. Middle East & Africa Cephalosporin Drugs Market Forecast, By Application 14.8.1. Respiratory Tract Infection 14.8.2. Skin Infection 14.8.3. Ear Infection 14.8.4. Urinary Tract Infection 14.8.5. Sexually Transmitted Infection 14.8.6. Others 14.9. Middle East & Africa Cephalosporin Drugs Market Value Share Analysis, by Country 14.10. Middle East & Africa Cephalosporin Drugs Market Forecast, by Country 14.10.1. GCC 14.10.2. South Africa 14.10.3. Rest of Middle East & Africa 14.11. Middle East & Africa Cephalosporin Drugs Market Analysis, by Country 14.12. GCC Cephalosporin Drugs Market Forecast, By Generation 14.12.1. First-generation 14.12.2. Second-generation 14.12.3. Third-generation 14.12.4. Fourth-generation 14.12.5. Fifth-generation 14.13. GCC Cephalosporin Drugs Market Forecast, By Route of Drug Administration 14.13.1. Injection 14.13.2. Oral 14.14. GCC Cephalosporin Drugs Market Forecast, By Application 14.14.1. Respiratory Tract Infection 14.14.2. Skin Infection 14.14.3. Ear Infection 14.14.4. Urinary Tract Infection 14.14.5. Sexually Transmitted Infection 14.14.6. Others 14.15. South Africa Cephalosporin Drugs Market Forecast, By Generation 14.15.1. First-generation 14.15.2. Second-generation 14.15.3. Third-generation 14.15.4. Fourth-generation 14.15.5. Fifth-generation 14.16. South Africa Cephalosporin Drugs Market Forecast, By Route of Drug Administration 14.16.1. Injection 14.16.2. Oral 14.17. South Africa Cephalosporin Drugs Market Forecast, By Application 14.17.1. Respiratory Tract Infection 14.17.2. Skin Infection 14.17.3. Ear Infection 14.17.4. Urinary Tract Infection 14.17.5. Sexually Transmitted Infection 14.17.6. Others 14.18. Rest of Middle East & Africa Cephalosporin Drugs Market Forecast, By Generation 14.18.1. First-generation 14.18.2. Second-generation 14.18.3. Third-generation 14.18.4. Fourth-generation 14.18.5. Fifth-generation 14.19. Rest of Middle East & Africa Cephalosporin Drugs Market Forecast, By Route of Drug Administration 14.19.1. Injection 14.19.2. Oral 14.20. Rest of Middle East & Africa Cephalosporin Drugs Market Forecast, By Application 14.20.1. Respiratory Tract Infection 14.20.2. Skin Infection 14.20.3. Ear Infection 14.20.4. Urinary Tract Infection 14.20.5. Sexually Transmitted Infection 14.20.6. Others 14.21. Middle East & Africa Cephalosporin Drugs Market Attractiveness Analysis 14.21.1. By Generation 14.21.2. By Route of Drug Administration 14.21.3. By Application 14.22. PEST Analysis 14.23. Key Trends 14.24. Key Developments 15. South America Cephalosporin Drugs Market Analysis 15.1. Key Findings 15.2. South America Cephalosporin Drugs Market Overview 15.3. South America Cephalosporin Drugs Market Value Share Analysis, By Generation 15.4. South America Cephalosporin Drugs Market Forecast, By Generation 15.4.1. First-generation 15.4.2. Second-generation 15.4.3. Third-generation 15.4.4. Fourth-generation 15.4.5. Fifth-generation 15.5. South America Cephalosporin Drugs Market Value Share Analysis, By Route of Drug Administration 15.6. South America Cephalosporin Drugs Market Forecast, By Route of Drug Administration 15.6.1. Injection 15.6.2. Oral 15.7. South America Cephalosporin Drugs Market Value Share Analysis, By Application 15.8. South America Cephalosporin Drugs Market Forecast, By Application 15.8.1. Respiratory Tract Infection 15.8.2. Skin Infection 15.8.3. Ear Infection 15.8.4. Urinary Tract Infection 15.8.5. Sexually Transmitted Infection 15.8.6. Others 15.9. South America Cephalosporin Drugs Market Value Share Analysis, by Country 15.10. South America Cephalosporin Drugs Market Forecast, by Country 15.10.1. Brazil 15.10.2. Mexico 15.10.3. Rest of South America 15.11. South America Cephalosporin Drugs Market Analysis, by Country 15.12. Brazil Cephalosporin Drugs Market Forecast, By Generation 15.12.1. First-generation 15.12.2. Second-generation 15.12.3. Third-generation 15.12.4. Fourth-generation 15.12.5. Fifth-generation 15.13. Brazil Cephalosporin Drugs Market Forecast, By Route of Drug Administration 15.13.1. Injection 15.13.2. Oral 15.14. Brazil Cephalosporin Drugs Market Forecast, By Application 15.14.1. Respiratory Tract Infection 15.14.2. Skin Infection 15.14.3. Ear Infection 15.14.4. Urinary Tract Infection 15.14.5. Sexually Transmitted Infection 15.14.6. Others 15.15. Mexico Cephalosporin Drugs Market Forecast, By Generation 15.15.1. First-generation 15.15.2. Second-generation 15.15.3. Third-generation 15.15.4. Fourth-generation 15.15.5. Fifth-generation 15.16. Mexico Cephalosporin Drugs Market Forecast, By Route of Drug Administration 15.16.1. Injection 15.16.2. Oral 15.17. Mexico Cephalosporin Drugs Market Forecast, By Application 15.17.1. Respiratory Tract Infection 15.17.2. Skin Infection 15.17.3. Ear Infection 15.17.4. Urinary Tract Infection 15.17.5. Sexually Transmitted Infection 15.17.6. Others 15.18. Rest of South America Cephalosporin Drugs Market Forecast, By Generation 15.18.1. First-generation 15.18.2. Second-generation 15.18.3. Third-generation 15.18.4. Fourth-generation 15.18.5. Fifth-generation 15.19. Rest of South America Cephalosporin Drugs Market Forecast, By Route of Drug Administration 15.19.1. Injection 15.19.2. Oral 15.20. Rest of South America Cephalosporin Drugs Market Forecast, By Application 15.20.1. Respiratory Tract Infection 15.20.2. Skin Infection 15.20.3. Ear Infection 15.20.4. Urinary Tract Infection 15.20.5. Sexually Transmitted Infection 15.20.6. Others 15.21. South America Cephalosporin Drugs Market Attractiveness Analysis 15.21.1. By Generation 15.21.2. By Route of Drug Administration 15.21.3. By Application 15.22. PEST Analysis 15.23. Key Trends 15.24. Key Developments 16. Company Profiles 16.1. Market Share Analysis, by Company 16.2. Competition Matrix 16.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment 16.2.2. New Product Launches and Product Enhancements 16.2.3. Market Consolidation 16.2.3.1. M&A by Regions, Investment and Applications 16.2.3.2. M&A Key Players, Forward Integration and Backward Integration 16.3. Company Profiles: Key Players 16.3.1. ABBOTT Laboratories 16.3.1.1. Company Overview 16.3.1.2. Financial Overview 16.3.1.3. Product Portfolio 16.3.1.4. Business Strategy 16.3.1.5. Recent Developments 16.3.1.6. Development Footprint 16.3.2. Aristo Pharmaceuticals Ltd 16.3.3. Baxter International 16.3.4. F. Hoffmann-La Roche AG 16.3.5. GlaxoSmithKline PLC 16.3.6. Lupin Pharmaceuticals Inc. 16.3.7. Macleods Pharmaceuticals Ltd 16.3.8. Mankind Pharma 16.3.9. Merck & Co. Inc. 16.3.10. Pfizer Inc. 16.3.11. Teva Pharmaceutical Industries Ltd 16.3.12. Orchid Pharma 16.3.13. Taj Pharmaceuticals 16.3.14. Covalent Laboratories 16.3.15. United Laboratories 16.3.16. Aurobindo 16.3.17. Astellas Pharma Inc. 16.3.18. Sanofi 16.3.19. Sun Pharmaceutical Industries Limited 16.3.20. Allergan Plc. 16.3.21. Bayer AG 16.3.22. BRISTOL-MYERS SQUIBB COMPANY 15. Primary Key Insights

Global Cephalosporin Drugs Market

Choose License Type